Bharat Immunological & Biological Corporation Ltd

As of 31-Oct, Bharat Immunological & Biological Corporation Ltd's stock price is declining at 20.28, down 1.51%, and has underperformed its sector and the benchmark Sensex significantly. The stock is on a bearish trend, trading below all major moving averages, with a year-to-date decline of 14.75% despite increased investor participation.

As of 24-Sep, Bharat Immunological & Biological Corporation Ltd's stock is at 21.54, down 0.23%, and has declined 1.96% over the last three days. The company faces significant challenges, including a drastic drop in net sales, high debt, and underperformance compared to market benchmarks, indicating a risky investment outlook.

As of 23-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is at 21.59, down 0.83%, and has underperformed the market with a total decline of 4.60% over the past month. The stock is trading below all key moving averages, indicating a bearish trend and decreased investor participation.

As of 22-Sep, Bharat Immunological & Biological Corporation Ltd is facing a decline in stock price at 21.77, with a short-term underperformance reflected in negative returns and trading below key moving averages. Despite a significant increase in delivery volume, the stock lags behind the broader market, which has shown positive momentum.

As of 19-Sep, Bharat Immunological & Biological Corporation Ltd is priced at 22.01, showing a slight increase but trading below all moving averages, indicating a bearish trend. The stock has underperformed significantly over longer periods, with a year-to-date decline of 7.48%, driven by weak fundamentals and declining investor interest.

As of 18-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is declining at 21.92, down 0.36%, and has underperformed its sector. The stock has dropped 24.98% over the past year and is trading below all major moving averages, indicating a bearish trend despite increased trading activity.

As of 17-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is 22.00, down 0.59%. The stock has underperformed its sector and benchmark indices, showing weak fundamentals and a lack of recent financial disclosures, which has led to low investor confidence.

As of 16-Sep, Bharat Immunological & Biological Corporation Ltd is priced at 22.13, showing a slight increase but underperforming against the Sensex and exhibiting weak long-term fundamentals. Despite a recent uptick, declining sales and high debt raise concerns about its investment viability.

As of 15-Sep, Bharat Immunological & Biological Corporation Ltd is experiencing a decline in its stock price, currently at 21.97, reflecting a bearish trend with significant drops in investor participation and underperformance compared to the benchmark Sensex. The stock has fallen 7.65% year-to-date, contrasting sharply with the Sensex's gain of 4.67%.

As of 12-Sep, Bharat Immunological & Biological Corporation Ltd's stock is at 22.00, down -0.81%, and has significantly underperformed its sector and the Sensex. The company faces weak fundamentals, declining sales, and a high debt-to-EBITDA ratio, indicating a challenging outlook and low investor confidence.

As of 11-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is at 22.18, showing a slight recovery today after a decline, but it has significantly underperformed over the past year and longer periods compared to the market. Despite a short-term gain, investor participation has dropped notably, indicating ongoing challenges for the company.

As of 10-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is declining at 21.70, down 1.05%, with a significant drop of 22.64% over the past year. The stock is underperforming compared to the market, with a year-to-date decline of 8.79% against the Sensex's increase of 4.21%.

As of 09-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is at 21.93, down 0.63%, and has been underperforming with a total decline of 2.49% over the last two days. The stock is trading below key moving averages, has weak fundamentals, and has consistently underperformed against the benchmark, indicating significant challenges in attracting investor confidence.

As of 08-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is at 22.07, down 1.87%, with significant underperformance year-to-date and over the past year. Despite short-term gains, the overall trend remains negative due to declining investor interest and poor long-term performance compared to the benchmark Sensex.

As of 05-Sep, Bharat Immunological & Biological Corporation Ltd's stock is priced at 22.49, showing a short-term increase but facing significant long-term challenges due to weak fundamentals, declining sales, and high debt levels. Despite recent positive performance, the stock has underperformed against the benchmark over the year, indicating a precarious long-term outlook.

As of 04-September, Bharat Immunological & Biological Corporation Ltd's stock price is at 22.05, down 3.67%. Despite a recent short-term gain, the stock has significantly underperformed over the year and remains below key moving averages.

As of 03-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is 22.89, up 3.25%. Despite recent short-term gains, the company faces long-term challenges, including a significant decline in net sales and high debt, leading to a perception of risk.